• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » An Antipsychotic Patch

An Antipsychotic Patch

November 15, 2019
Chris ­Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris ­Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Asenapine (Saphris) is now available as a transdermal patch, Secuado. The patch showed efficacy in a large 6-week, double-blind, placebo-controlled, fixed-dose study in 616 adult patients with schizophrenia.


Transdermal medications are thought to reduce side effects by avoiding “first-pass” metabolism in the GI tract. This is unlikely to be an advantage for Secuado, however, because the sublingual form of asenapine (Saphris) already avoids the first-pass effect by absorbing through the buccal membrane. Compared to placebo, Secuado’s side effect profile looks identical to Saphris, except that it adds one more: skin irritation (15%). Still, some patients may prefer it to Saphris, which is notorious for its unpleasant taste that is not always masked by its black cherry flavoring.


The main difference between Saphris and Secuado is in their pharmacokinetics. Saphris comes on fast, peaking within an hour, while Secuado takes 12–24 hours to reach peak levels. Peak levels are associated with side effects, however, not efficacy. Some patients do better with lower levels spread out over a long time (Secuado), while others prefer the rapid up and rapid down of Saphris. In other words, Secuado is to Saphris as Seroquel XR is to Seroquel IR.


Secuado’s advantages over Saphris are dampened when Saphris is given as a single nightly dose. This minimizes fatigue by concentrating the side effects in the evening. Although it’s recommended to divide Saphris twice daily, there is little reason to do so either in schizophrenia or bipolar disorder. Antipsychotics can be given in a single daily dose without loss of efficacy, according to 4 randomized controlled trials (Takeuchi H et al, J Clin Psychiatry 2014;75(5):506–511). That is true for antipsychotics with short half-lives like perphenazine and clozapine, and makes even more sense with the 24-hour half-life of Saphris.


Secuado and Saphris have never been directly compared, but industry-sponsored papers touting the benefits of the transdermal form are already on the march (Citrome L et al, J Clin Psychiatry 2019;80(4)). Caution: These papers draw their arguments from transdermal systems designed for other diagnoses like ADHD and dementia. There the comparison is an oral medication given twice a day, not a sublingual one given all at night. Secuado may be right for patients whose side effects are tied to asenapine’s peak plasma levels. Otherwise, Saphris is the better choice, particularly after December 2020 when it is expected to go generic.



Table: Secuado Patch vs Saphris Sublingual


Table: Secuado Patch vs Saphris Sublingual


View as full-size PDF.


General Psychiatry
KEYWORDS antipsychotic asenapine news_of_note patch saphris secuado transdermal
Chris ­Aiken, MD.

Uncommon Tips: Which Is Better—Citalopram or Escitalopram?

More from this author
www.thecarlatreport.com
Issue Date: November 15, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Adult ADHD, TCPR, November/December 2019
Highlights From This Issue
Adult-Onset ADHD
Micronutrients in Mental Health
Adult ADHD: What Else Could It Be?
Stimulants as Cognitive Enhancers
A Practical Guide to Light Therapy
Meet the First H3 Antagonist
An Antipsychotic Patch
Pharmacology for GAD: Complex Choices
Olanzapine for Anorexia Nervosa
In Brief: Antipsychotic Update
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.